Breast Cancer Trial, Not Yet Recruiting NCT07419711 Sponsor: Nazarbayev University Condition: Breast Cancer
Back to Breast Cancer

Breast Cancer Trial, Not Yet Recruiting

NCT07419711
Not Yet Recruiting Not Applicable

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • Women between 30 and 75 years of age.
  • People who have been diagnosed with breast cancer confirmed through a tissue sample test.
  • People who are planned to receive a type of chemotherapy that includes drugs called anthracyclines and/or trastuzumab.
  • People assessed by their doctor as having a high or very high chance (20% or more) of developing heart-related side effects from chemotherapy.
  • People with a general health and activity level rated between 0 and 3 on a standard medical scale (meaning able to carry out at least some self-care, up to fully active).
  • People who are able to swallow and take oral (by mouth) study products.
  • People who are willing to follow the study procedures and attend follow-up visits.
  • People who have given written agreement to participate before any study procedures begin.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People with a general health and activity level rated as 4 on the standard medical scale (meaning completely unable to carry out self-care and confined to bed or chair).
  • People with serious pre-existing heart or blood vessel disease that would interfere with taking part in the study.
  • People with permanent atrial fibrillation (an irregular heart rhythm) or other significant heart rhythm problems.
  • People with severely reduced liver or kidney function.
  • People with active tumours or cancer spread to the brain or central nervous system.
  • People with high blood pressure that is not under control.
  • People with ongoing digestive system conditions that may affect how the body absorbs the study products.
  • People with a known allergy or intolerance to grape products or any components of the study products.
  • People already taking part in another interventional clinical trial that could affect the results of this study.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 29 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +77054448869

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Not Applicable
Sponsor
Nazarbayev University
Registry
ClinicalTrials.gov
Start date
9 February 2026
Est. completion
9 May 2026

This date has passed while the registry still lists the trial as open to participants. Sponsors often update a trial's status without revising its projected end date, so it may well still be recruiting — but the record is out of date in at least one respect. Check with the study contact before relying on either.

Primary endpoints

Change in High-Sensitivity Troponin Levels; Change in NT-proBNP Levels; Change in Left Ventricular Ejection Fraction (LVEF); Change in Global Longitudinal Strain (GLS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 29 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov